ASX
LCT 0.060    Last updated 9.21 pm
Fact sheet
The following fact sheets provide a summary of our current business and research pipeline.
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.

Fact sheet

The following fact sheets provide a summary of our current business and research pipeline.

Cell therapy for neurodegenerative diseases

Living Cell Technologies Limited (LCT) is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercialising regenerative treatments which restore function using naturally occurring cells.

 

LCT’s lead product NTCELL® is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation NTCELL functions as a biological factory producing nerve growth factors to promote new central nervous system growth and repair disease induced nerve degeneration.

 

NTCELL is in Phase I/IIa clinical trial in New Zealand for the treatment of Parkinson’s disease. It has the potential to be used in a number of other central nervous system indications such as Huntington’s, Alzheimer’s and motor neurone diseases.

 

LCT’s proprietary encapsulation technology, IMMUPEL™, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system.

 

LCT holds a 50% interest in Diatranz Otsuka Limited which is developing a cell therapy for type 1 diabetes.

 

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in New Zealand.

— 24 April 2015

Appendix 4C Quarterly Report 31 March 2015

Living Cell Technologies Limited today released its cash flow report for the quarter ended 31 March 2015. The company ended the quarter with a cash balance of $6,349,884 compared to $6,972,225 in the previous quarter. The decrease is due to normal operating costs and the cost of continuing to monitor clinical trial patients.

Read More Read Less

— 5 March 2015

JV adopts new strategy for DIABECELL

LCT's 50% owned joint venture Diatranz Otsuka Limited (DOL) has adopted a new development strategy for DIABECELL®. DOL will partner with its other 50% shareholder, Otsuka Pharmaceutical Factory, Inc. (OPF) to support the development and launch of DIABECELL in United States of America. DOL retains a royalty-free right to commercialise DIABECELL outside USA and Japan.

Read More Read Less
Load More

— 8 May 2014

Please refer to our news releases

Load More
— 15 June 2015

International Congress of Parkinson's Disease and Movement Disorders. "Safety and clinical effects of NTCELL® in patients with Parkinson's disease: 26 weeks follow-up." 12:30 - 14:00 Coronado Ballroom (Level 4) Manchester Grand Hyatt San Diego 1 Market Place San Diego, California, USA, 92101

— 10 November 2015

LCT Annual General Meeting. To be held in Auckland, New Zealand.

Load More
Announcements

— 24 April 2015

Appendix 4C Quarterly Report 31 March 2015

Living Cell Technologies Limited today released its cash flow report for the quarter ended 31 March 2015. The company ended the quarter with a cash balance of $6,349,884 compared to $6,972,225 in the previous quarter. The decrease is due to normal operating costs and the cost of continuing to monitor clinical trial patients.

Read More Read Less

— 5 March 2015

JV adopts new strategy for DIABECELL

LCT's 50% owned joint venture Diatranz Otsuka Limited (DOL) has adopted a new development strategy for DIABECELL®. DOL will partner with its other 50% shareholder, Otsuka Pharmaceutical Factory, Inc. (OPF) to support the development and launch of DIABECELL in United States of America. DOL retains a royalty-free right to commercialise DIABECELL outside USA and Japan.

Read More Read Less
Load More
LCT in the News

— 8 May 2014

Please refer to our news releases

Load More
Events
— 15 June 2015

International Congress of Parkinson's Disease and Movement Disorders. "Safety and clinical effects of NTCELL® in patients with Parkinson's disease: 26 weeks follow-up." 12:30 - 14:00 Coronado Ballroom (Level 4) Manchester Grand Hyatt San Diego 1 Market Place San Diego, California, USA, 92101

— 10 November 2015

LCT Annual General Meeting. To be held in Auckland, New Zealand.

Load More
© 2015 Living Cell Technologies Limited.
site by { brownpaperbag }